Group 1 - The company, Huaxia Eye Hospital Group Co., Ltd., has announced that it will not distribute cash dividends, issue bonus shares, or increase capital reserves during the reporting period [2][3] - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [4] - The company completed the distribution of cash dividends amounting to RMB 183,143,875.20 on July 14, 2025, with a distribution of RMB 2.20 per 10 shares [4]

Meeting Overview - The third board meeting of Huaxia Eye Hospital Group Co., Ltd. was held on August 21, 2025, combining both in-person and remote attendance [1] - All 7 board members attended the meeting, with one member represented by proxy due to personal reasons [1] - The meeting was chaired by Mr. Chen Fengguo, and it complied with relevant regulations [1] Resolutions Passed - All resolutions were passed unanimously with 7 votes in favor, 0 against, and 0 abstentions [2][3][4] - The resolutions included the approval of the semi-annual report and the special report on the management and use of raised funds [2][4] - A proposal to amend the company's articles of association was approved, which will eliminate the supervisory board, transferring its powers to the audit committee of the board [2][4] Future Actions - Several resolutions are pending submission to the shareholders' meeting for further approval [2][3][4] - The company will publish detailed information regarding the resolutions on its official website [5]

| 2025 | | 华厦眼科医院集团股份有限公司 | 年半年度报告摘要 | | | --- | --- | --- | --- | --- | | 证券代码：301267 | | 证券简称：华厦眼科 | 公告编号：2025-025 | | | 华厦眼科医院集团股份有限公司 | | | | | | 华厦眼科医院集团股份有限公司 | | | | 2025 年半年度报 | | 告摘要 | | | | | | 一、重要提示 | | | | | | 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 | | | | | | 资者应当到证监 | | | | | | 会指定媒体仔细阅读半年度报告全文。 | | | | | | 除下列董事外，其他董事亲自出席了审议本次半年报的董事会会议 | | | | | | 未亲自出席董事姓名 | | 未亲自出席董事职务 | 未亲自出席会议原 | | | 因 | | 被委托人姓名 | | | | 苏庆灿 | | 董事长 | 因个人原 | | | 因 | | 陈凤国 | | | | 非标准审计意见提示 | | | | | | □适用 | ?不适用 | ...

Meeting Overview - The third supervisory board meeting of Huaxia Eye Hospital Group Co., Ltd. was held on August 21, 2025, combining both in-person and remote attendance [1] - All three supervisors attended the meeting, which was chaired by Ms. Huang Niya, and complied with relevant regulations [1] Resolutions Passed - The supervisory board unanimously approved the written confirmation of the 2025 semi-annual report, ensuring its authenticity and completeness, with a voting result of 3 in favor, 0 against, and 0 abstentions [1] - The supervisory board confirmed that the report on the management and use of raised funds for the first half of 2025 accurately reflects the company's situation and complies with legal requirements, with the same voting result [2] - The board agreed to extend the implementation period for certain fundraising projects, stating that this does not change the amount of funds or the direction of investment, nor does it materially affect the company's financial status or shareholder interests, with a voting result of 3 in favor, 0 against, and 0 abstentions [2][3]

Meeting Announcement - Huaxia Eye Hospital Group Co., Ltd. will hold its first extraordinary general meeting of shareholders for 2025 on September 10, 2025, at 15:00 [1] - The meeting will be conducted both in-person and via online voting [1][2] Voting Procedures - Shareholders can vote through the Shenzhen Stock Exchange trading system and internet voting system during specified times on September 10, 2025 [2][4] - Only one voting method (in-person or online) can be chosen for each voting right, and duplicate votes will be counted as the first vote [2] Shareholder Eligibility - Shareholders registered by the cut-off date of September 3, 2025, at 15:00 are eligible to attend and vote [2] - Shareholders unable to attend can authorize a proxy to represent them, who does not need to be a shareholder [2] Agenda Items - The meeting will review several proposals, including the cancellation of the supervisory board and amendments to the company's articles of association [3][8] - Certain proposals require a special resolution, needing approval from at least two-thirds of the voting rights represented at the meeting [3] Registration Details - Natural person shareholders must present valid identification for registration, while corporate shareholders must provide proof of their legal representative status [4] - Remote shareholders must register via mail or fax, with the time of receipt being the determining factor [4] Voting Process Details - Specific procedures for online voting will be provided, including identity verification requirements [5]

Core Viewpoint - The company has decided to extend the implementation period for certain fundraising investment projects to optimize resource allocation and improve the efficiency of fundraising usage, aligning with its long-term development strategy [5]. Group 1: Fundraising Project Overview - The company raised a total of RMB 276,849.25 million through its initial public offering, with a share price of RMB 50.88 per share for 60 million shares [1]. - The total investment for the fundraising projects is RMB 778,506,100, with the company having excess funds of RMB 198,998.64 million after accounting for project needs [2]. Group 2: Extension of Implementation Period - The company plans to extend the implementation period for the "Information Management System Construction Project" from October 28, 2025, to December 31, 2027, to meet growing business needs and enhance patient experience [4]. - The project involves a total investment of RMB 20,386.80 million, fully funded by the raised capital, and includes components such as remote consultation systems and electronic medical records [4]. Group 3: Impact of the Extension - The decision to extend the project timeline is based on the company's future development plans and the actual progress of the fundraising projects, ensuring no adverse effects on project implementation or shareholder interests [5]. - The extension does not involve changes to the total investment amount, the amount of raised funds allocated, or the implementation methods of the projects [5]. Group 4: Decision-Making Process and Verification - The board of directors and the supervisory board approved the extension on August 21, 2025, within the board's authority, eliminating the need for shareholder approval [5]. - The sponsoring institution has verified that the extension complies with relevant regulations and does not alter the intended use of the raised funds [5].

Core Points - The "Brilliant Vision" charity event in Tibet aims to promote technical exchanges in ophthalmology between Beijing and Tibet, enhancing the transfer of high-quality medical resources to the region by 2025 [1][2] - The event is led by Wei Wenbin, Vice President of Beijing Tongren Hospital, and involves a volunteer medical team providing assistance in four hospitals across three regions in Tibet [1][2] Medical Assistance - The charity event completed 60 cataract surgeries and 20 complex vitreoretinal surgeries, marking the first complex artificial lens suspension surgery in the region [2] - Health consultations and large-scale health outreach activities were conducted, benefiting the local population, along with training for local ophthalmologists [2][5] - The expert team identified a high incidence of retinal vascular occlusion due to hypertension and hyperlipidemia, emphasizing the need for better management of chronic eye diseases in the region [5][8] Training and Technology - The event included training sessions for local ophthalmologists on technical standards and practical laser operations, addressing the unique challenges of healthcare in remote areas [2][8] - Wei Wenbin suggested utilizing AI to enhance diagnostic capabilities and facilitate remote consultations, allowing national experts to support the region [8]

Group 1 - The core viewpoint of the article is that Huaxia Eye Hospital (301267) reported its semi-annual financial results, showing growth in both revenue and net profit [1] - The company achieved a revenue of 2.139 billion yuan in the first half of the year, representing a year-on-year increase of 4.31% [1] - The net profit attributable to shareholders was 282 million yuan, reflecting a year-on-year growth of 6.2% [1]

Core Insights - Huaxia Eye Hospital (301267) reported its semi-annual results for 2025, showing a revenue of 2.139 billion yuan, representing a year-on-year growth of 4.31% [1] - The net profit attributable to shareholders reached 282 million yuan, with a year-on-year increase of 6.2% [1] - Basic earnings per share were reported at 0.34 yuan [1]

格隆汇8月24日丨华厦眼科(301267.SZ)公布2025年半年度报告，报告期实现营业收入21.39亿元，同比增 长4.31%；归属于上市公司股东的净利润2.82亿元，同比增长6.20%；归属于上市公司股东的扣除非经常 性损益的净利润2.78亿元，同比增长2.43%；基本每股收益0.34元。 ...